## Publications:

Santos AN, Rauschenbach L, Saban D, *et al.* Natural Course of Cerebral Cavernous Malformations in Children: A Five-Year Follow-Up Study. *Stroke*. 2021: STROKEAHA121035338.

Herten A, Chen B, Saban D, et al. Health-related quality of life in patients with untreated cavernous malformations of the central nervous system. Eur J Neurol. 2021 28: 491-499.

Dammann P, Saban DV, Herten A, *et al.* Cerebral cavernous malformations: Prevalence of cardiovascular comorbidities and allergic diseases compared to the normal population. *Eur J Neurol.* 2021.

Chen B, Saban D, Rauscher S, et al. Modifiable Cardiovascular Risk Factors in Patients With Sporadic Cerebral Cavernous Malformations: Obesity Matters. *Stroke*. 2021 **52**: 1259-1264.

Wan X, Saban DV, Kim SN, et al. PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma. *Front Oncol.* 2020 **10:** 1377.

Saban D, Larisch J, Nickel AC, *et al.* DNA promoter methylation of CCM genes in human cerebral cavernous malformations: Importance of confirming MSP data through sequencing. *Eur J Med Genet.* 2020 **63:** 104090.

Chen B, Herten A, Saban D, *et al.* Hemorrhage from cerebral cavernous malformations: The role of associated developmental venous anomalies. *Neurology*. 2020 **95:** e89-e96.

Nickel AC, Wan XY, Saban DV, et al. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma. J Neurooncol. 2019 141: 31-41.

Darkwah Oppong M, Skowronek V, Pierscianek D, *et al.* Aneurysmal intracerebral hematoma: Risk factors and surgical treatment decisions. *Clin Neurol Neurosurg.* 2018 **173:** 1-7.

Herrmann US, Schutz AK, Shirani H, et al. Structure-based drug design identifies polythiophenes as antiprion compounds. Sci Transl Med. 2015 7: 299ra123.

Falsig J, Sonati T, Herrmann US, et al. Prion pathogenesis is faithfully reproduced in cerebellar organotypic slice cultures. PLoS Pathog. 2012 8: e1002985.